investors.revance.comInvestor Relations - Revance Therapeutics, Inc.
investors.revance.com Profile
investors.revance.com
Maindomain:revance.com
Title:Investor Relations - Revance Therapeutics, Inc.
Description：The Investor Relations website contains information about Revance Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
Discover investors.revance.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investors.revance.com Information
| Website / Domain: | investors.revance.com |
| HomePage size: | 76.38 KB |
| Page Load Time: | 0.952522 Seconds |
| Website IP Address: | 184.50.88.76 |
| Isp Server: | Akamai Technologies Inc. |
investors.revance.com Ip Information
| Ip Country: | United States |
| City Name: | San Jose |
| Latitude: | 37.339389801025 |
| Longitude: | -121.89495849609 |
investors.revance.com Keywords accounting
| Keyword | Count |
|---|
investors.revance.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1592906643" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Tue, 23 Jun 2020 10:04:03 GMT |
| Link: http://investors.revance.com/; rel="shortlink", https://investors.revance.com/investor-relations; rel="canonical", https://investors.revance.com/investor-relations; rel="alternate"; hreflang="en", https://investors.revance.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| Server: nginx |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-dde67b5e-b538-11ea-a7f8-0bf25605cf03 |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| X-EdgeConnect-MidMile-RTT: 47 |
| X-EdgeConnect-Origin-MEX-Latency: 619 |
| X-Akamai-Transformed: 9 13736 0 pmb=mRUM,1 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Tue, 23 Jun 2020 10:04:04 GMT |
| Date: Tue, 23 Jun 2020 10:04:04 GMT |
| Content-Length: 14116 |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
| Strict-Transport-Security: max-age=15768000 ; preload |
investors.revance.com Meta Info
| charset="utf-8"/ |
| content="Revance Therapeutics, Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Revance Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="https://investors.revance.com/investor-relations" property="og:url"/ |
| content="Investor Relations - Revance Therapeutics, Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Revance Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
184.50.88.76 Domains
| Domain | WebSite Title |
|---|
investors.revance.com Similar Website
| Domain | WebSite Title |
|---|---|
| Investor Relations - Revance Therapeutics, Inc. | |
| Investor Relations | TG Therapeutics, Inc. | |
| Investor Relations TG Therapeutics Inc | |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) | |
| Revance Therapeutics - Crunchbase Company Profile & Funding | |
| Universal Technical Institute's Investor Relations - UTI Investor Relations | |
| Choice Hotels International - Investor Relations Home - Investor Relations | |
| Equitable Bank Investor Relations - Investor Relations - Overview | |
| 51Talk Investor Relations - Investor Relations Home | |
| Investor Relations - American Express Investor Relations | |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations | |
| INVESTOR OVERVIEW Insys Therapeutics Inc | |
| Investor Overview | Mateon Therapeutics | |
| Investor Overview | Mateon Therapeutics | |
| Investor Relations | Investor Relations | Littelfuse |
investors.revance.com Traffic Sources Chart
investors.revance.com Alexa Rank History Chart
investors.revance.com Html To Plain Text
Skip to main navigation Back Menu Aesthetics Back Aesthetics Overview RHA® HintMD Neuromodulator Neuromodulator Uses Clinical Highlights Therapeutics Back Therapeutics Overview Our Science Muscle Movement Disorders Pain Disorders Clinical Highlights Investors Back Investors LATEST NEWS Our Latest May 19, 2020 Revance announces addition of fintech platform for aesthetic practices with acquisition of HintMD All News Investor Relations Press Releases Events & Webcasts Corporate Governance Financials & Filings Stock Information Analyst Coverage Investor FAQ Company Back Company OUR LATEST Our Latest May 19, 2020 Revance announces addition of fintech platform for aesthetic practices with acquisition of HintMD Our Latest Overview About Revance Leadership Team Board of Directors Partnerships Contact Revance Contact Medical Affairs Corporate Social Responsibility News Careers Back Careers Overview Career Opportunities Culture Benefits & Perks facebook instagram twitter linkedin 7555 Gateway Boulevard Newark, California 94560 +1 (510) 742-3400 © Copyright 2020 All Rights Reserved Terms of Use Privacy Policy Data Provided by Refinitiv. Minimum 15 minutes delayed. Investor Relations Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Read More Breadcrumb Home Investor Relations Investor Relations Events UPCOMING AND ARCHIVED Events and Webcasts Read More News CURRENT AND ARCHIVED Press Releases Read More Presentations CURRENT AND HISTORICAL Presentations and Corporate Materials Read More Financials SEC FILINGS Financials and Filings Read More Stocks QUOTE | HISTORICAL | CALCULATOR Stock Information Read More Analyst SELL SIDE Analyst Coverage Read More Governance MANAGEMENT | BOARD | COMMITTEES Corporate Governance Read More FAQs GENERAL INFORMATION Frequently Asked Questions Read More Investor Inquiries Contact Jeanie Herbert jherbert@revance.com (714) 325 3584 More Contacts Revance - Shareholder Tools Print Page Printed Materials Email Alerts Download Library RSS News Feeds Share Search Keep up with Revance Subscribe 7555 Gateway Boulevard Newark, California 94560 +1 (510) 742-3400 facebook instagram twitter linkedin Aesthetics Overview RHA® HintMD Neuromodulator Neuromodulator Uses Clinical Highlights Therapeutics Overview Our Science Muscle Movement Disorders Pain Disorders Clinical Highlights Investors Investor Relations Press Releases Events & Webcasts Corporate Governance Financials & Filings Stock Information Analyst Coverage Investor FAQ Company Overview About Revance Leadership Team Board of Directors Partnerships Contact Revance Contact Medical Affairs Corporate Social Responsibility News All News In the News Our Latest Careers Overview Career Opportunities Culture Benefits & Perks © Copyright 2020 All Rights Reserved Terms of Use Privacy Policy Back to top Facebook LinkedIn...
investors.revance.com Whois
"domain_name": "REVANCE.COM",
"registrar": "Network Solutions, LLC",
"whois_server": "whois.networksolutions.com",
"referral_url": null,
"updated_date": "2019-12-06 12:49:06",
"creation_date": "2000-07-05 18:33:11",
"expiration_date": "2021-07-05 18:33:11",
"name_servers": [
"NS1-03.AZURE-DNS.COM",
"NS2-03.AZURE-DNS.NET",
"NS3-03.AZURE-DNS.ORG",
"NS4-03.AZURE-DNS.INFO"
],
"status": "clientTransferProhibited https://icann.org/epp#clientTransferProhibited",
"emails": "abuse@web.com",
"dnssec": "unsigned",
"name": null,
"org": null,
"address": null,
"city": null,
"state": null,
"zipcode": null,
"country": null